Topical Nanoformulations of Apremilast for Psoriasis Therapy

Sindhoor S M

$75.95 $64.25

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Mohammed Abdul Sattar
30 January 2024

Immunology; Dermatology

Summary
Details

Psoriasis is considered a chronic, inflammatory autoimmune disorder of the skin affecting 2-5% of the world's population and is characterized by inflamed reddish erythematous plaques. There are several therapeutic drugs available for the treatment of psoriasis. Despite this, none of them is entirely safe and effective in treating the condition without jeopardizing patient compliance. Traditional topical therapies have significant drawbacks, including inadequate drug penetration, higher dose frequency, severe toxicity, and poor patient compliance.

Phototherapy and systemic drugs employed in psoriasis therapy have many side effects such as hepatotoxicity, nephrotoxicity, skin cancer and high blood pressure. These complications limit the usage of currently available psoriasis treatments. Thus there is a need to look out for alternative moiety or advanced delivery systems which overcome the limitations of the current therapeutic regimens for psoriasis. Apremilast (APM) is a type 4 phosphodiesterase inhibitor authorized to treat psoriasis and psoriatic arthritis worldwide. It has low solubility and permeability and is hence categorized as a BCS class IV drug.

The topical application of apremilast directly to the affected skin will avoid the problems associated with oral administration, and also, dose reduction is possible since the first-pass metabolism can be bypassed. However, due to apremilast's poor aqueous solubility, permeability and modest lipophilicity, it is not easy to deliver it to across the scaly psoriasis lesions through conventional topical formulations. The use of topical nanoformulations, especially lipid nanocarriers, can overcome the limitations mentioned above and permeate psoriatic horny layers and retain the drug in the skin layers.

By: Sindhoor S M
Imprint: Mohammed Abdul Sattar
Dimensions: Height: 279mm, Width: 216mm, Spine: 10mm
Weight: 445g
ISBN: 9798224424832
Pages: 186
Publication Date: 30 January 2024
Audience: General/trade , ELT Advanced
Format: Paperback
Publisher's Status: Active

THE BIG SALE IS ON! TELL ME MORE

Topical Nanoformulations of Apremilast for Psoriasis Therapy

Sindhoor S M

$75.95 $64.25

Paperback

See Also

Contact Abbeys

Contact Galaxy

Contact Language

Contact Us

About ABBEY'S